**eTable 1: Baseline characteristics according to nodal status.**

|  |  |  |
| --- | --- | --- |
|  | **Node-negative****(N=591)** | **Node-positive****(N=183)** |
| **Mean age, years (SD)** | 63.4 (7.9) | 66.4 (8.3) |
| **Mean BMI, kg/m2 (SD)** | 27.3 (4.9) | 26.7 (4.7) |
| **Grade** |  |  |
|  1 | 23.2% | 21.9% |
|  2 | 59.7% | 58.5% |
|  3 | 17.1% | 19.7% |
| **Mean tumour size, mm (SD)** | 17.6 (8.5) | 24.2 (12.2) |
| **Distant recurrence** |  |  |
|  **0-10 years** | 58 (9.8%) | 40 (21.9%) |
|  **5-10 years** | 34/535 (6.4%) | 21/154 (13.6%) |

SD=Standard Deviation, kg-kilogram, m=metre, mm=millimetre

**eTable 2: C-indices and Likelihood Ratio Chi Square for prognostic information of each signature on its own (LR-χ2), added prognostic value (∆LR-χ2), number of women in each risk group, and 10-year distant recurrence (DR) risk for all women in years 0-10 (N=774) and years 5-10 (N=689).**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **C-index (95% CI)** | **LR-χ²** | **∆LR-χ²** | **Number of women in risk group (low/intermediate/high)** | **10-year DR risk****(low/intermediate/high)** |
|  | **Years 0-10 (N=774)** |
| CTS | 0.726 (0.683-0.768) | 55.3 | - | - | - |
| IHC4 | 0.680 (0.630-0.731) | 31.7 | 20.1 | - | - |
| BCI | 0.727 (0.680-0.744) | 55.8 | 32.8 | 460/203/111 | 6.3%/23.0%/30.6% |
| RS | 0.645 (0.584-0.706) | 26.9 | 15.2 | 479/214/81 | 8.7%/20.1%/29.9% |
| ROR (no tumor size) | 0.716 (0.668-0.763) | 56.2 | 27.4 | - | - |
| ROR | 0.725 (0.679-0.772) | 61.5 | 26.3 | 333/236/205 | 2.9%/15.7%/31.4% |
| EP | 0.705 (0.658-0.752) | 42.7 | 23.7 | 323/-/451 | 5.5%/-/20.1% |
| EPclin | 0.753 (0.713-0.793) | 69.3 | 24.4 | 472/-/302 | 6.5%/-/25.9% |
|  | **Years 5-10 (N=689)** |
| CTS | 0.725 (0.671-0.779) | 28.2 | - | - | - |
| IHC4 | 0.634 (0.566-0.702) | 8.3 | 4.5 | - | - |
| BCI | 0.717 (0.651-0.782) | 27.4 | 16.5 | 424/176/89 | 3.9%/16.2%/18.6% |
| RS | 0.574 (0.485-0.662) | 6.3 | 3.0 | 445/179/65 | 6.9%/10.6%/17.6% |
| ROR (no tumor size) | 0.729 (0.667-0.790) | 35.1 | 19.0 | - | - |
| ROR | 0.745 (0.687-0.804) | 40.0 | 20.0 | 307/216/166 | 1.4%/10.7%/21.5% |
| EP | 0.707 (0.645-0.769) | 23.8 | 14.2 | 294/-/395 | 2.7%/-/13.4% |
| EPclin | 0.761 (0.707-0.815) | 41.6 | 17.3 | 433/-/256 | 4.2%/-/16.9% |

LR=Likelihood Ratio, CI=Confidence Interval, DR=Distant Recurrence, CTS=Clinical Treatment Score, IHC4=Immunohistochemical Score, BCI=Breast Cancer Index, RS=Recurrence Score, ROR=Risk of Recurrence Score, EP=EndoPredict, EPclin=EndoPredict clinical

**eFigure 1: CONSORT diagram.**



ATAC=Arimidex Tamoxifen Alone or in Combination, ER=Oestrogen Receptor, PgR=Progesterone Receptor, CTS=Clinical Treatment Score, IHC4=Immunohistochemical Score, BCI=Breast Cancer Index, RS=Recurrence Score, ROR=Risk of Recurrence Score, EPclin=EndoPredict clinical

**eFigure 2: Likelihood Ratio Chi Square for prognostic information of each signature on its own (LR-χ2) and when added to CTS (∆LR-χ2) in years 0-10 for node-negative patients (left) and node-positive patients (right). Dotted line indicates significance level of 5% (LR-χ2=3.84).**

****

CTS=Clinical Treatment Score, IHC4=Immunohistochemical Score, BCI=Breast Cancer Index, RS=Recurrence Score, ROR=Risk of Recurrence Score,EPclin=EndoPredict clinical

**eFigure 3: Likelihood Ratio Chi Square for prognostic information of each signature on its own (LR-χ2) and when added to CTS (∆LR-χ2) in years 5-10 for node-negative patients (left) and node-positive patients (right). Dotted line indicates significance level of 5% (LR-χ2=3.84).**

****

CTS=Clinical Treatment Score, IHC4=Immunohistochemical Score, BCI=Breast Cancer Index, RS=Recurrence Score, ROR=Risk of Recurrence Score,EPclin=EndoPredict clinical